Publication | Closed Access
Effect of recombinant human erythropoietin on vascular access.
17
Citations
0
References
1992
Year
Blood CellDialysis TherapyAplastic AnemiaThrombosisHematologyVascular SurgeryChronic Kidney DiseaseHemodialysisKidney TransplantRecombinant Human ErythropoietinVascular BiologyGraft ThrombosisBlood DonationUrologyChronic HemodialysisVascular AccessMedicineNephrologyBlood Transfusion
The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.